Cargando…
The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer
BACKGROUND: Oxaliplatin, irinotecan, 5-fluorouracil, and l-leucovorin (FOLFIRINOX) has become one of the first-line treatment options for advanced pancreatic cancer (PC). However, the relatively high rate of grade 3 or 4 adverse events associated with the standard dosage of FOLFIRINOX limits its wid...
Autores principales: | Wang, Zhi-Qiang, Zhang, Fei, Deng, Ting, Zhang, Le, Feng, Fen, Wang, Feng-Hua, Wang, Wei, Wang, De-Shen, Luo, Hui-Yan, Xu, Rui-Hua, Ba, Yi, Li, Yu-Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507030/ https://www.ncbi.nlm.nih.gov/pubmed/31068222 http://dx.doi.org/10.1186/s40880-019-0367-7 |
Ejemplares similares
-
Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer
por: Chen, Jiayuan, et al.
Publicado: (2021) -
Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure
por: Kobayashi, Noritoshi, et al.
Publicado: (2017) -
Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S‐1 as second‐line chemotherapy in metastatic pancreatic cancer
por: Ikezawa, Kenji, et al.
Publicado: (2021) -
Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges
por: Yang, Feng, et al.
Publicado: (2019) -
Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
por: Klein-Brill, Avital, et al.
Publicado: (2022)